The United States Patent and Trademark Office (USPTO) has granted NADMED its first U.S. patent. The patent was issued on 10 November 2026. It covers NADMED’s method for extracting NAD metabolites, and glutathione with them, from whole blood. This method is the foundation of the company’s assays.
The patent names two NADMED co-founders as inventors: Liliya Euro, PhD, Chief Scientific Officer, and Professor Anu Wartiovaara of the University of Helsinki, Chair of the Board. It recognizes their scientific work at the University of Helsinki, on which NADMED was founded. The grant comes more than six years after the first application was filed in 2020.
The patent protects the method at the core of NADMED’s technology and supports the company’s long-term strategy of growing its scientific and commercial presence internationally.
Read the press release here.